Every GLP-1 product Novo Nordisk A/S lists
One row per product NDC, in FDA’s words. Strength is printed as FDA lists it, spacing tidied.
| Product | Product NDC | Form and strength | FDA category | Listed | Packages |
|---|---|---|---|---|---|
| semaglutide | 0420-9237 | Injection, Solution0.68 mg/mL | Unfinished, for further processingDRUG FOR FURTHER PROCESSING | Since Dec 6, 2017Certified through Dec 31, 2026 | 1 package
|
| semaglutide | 0420-9600 | Injection, Solution2.68 mg/mL | Unfinished, for further processingDRUG FOR FURTHER PROCESSING | Since Apr 29, 2026Certified through Dec 31, 2027 | 1 package
|
| Semaglutide | 0420-9300 | Injection, Solution0.5 mg/0.5 mL | Unfinished, for further processingDRUG FOR FURTHER PROCESSING | Since Jun 2, 2017Certified through Dec 31, 2027 | 1 package
|
| Semaglutide | 0420-9301 | Injection, Solution0.25 mg/0.5 mL | Unfinished, for further processingDRUG FOR FURTHER PROCESSING | Since May 7, 2026Certified through Dec 31, 2027 | 1 package
|
| Semaglutide | 0420-9302 | Injection, Solution1 mg/0.5 mL | Unfinished, for further processingDRUG FOR FURTHER PROCESSING | Since Apr 28, 2026Certified through Dec 31, 2027 | 1 package
|
| Semaglutide | 0420-9317 | Injection, Solution1.7 mg/0.75 mL | Unfinished, for further processingDRUG FOR FURTHER PROCESSING | Since Apr 28, 2026Certified through Dec 31, 2027 | 1 package
|
| Semaglutide | 0420-9324 | Injection, Solution2.4 mg/0.75 mL | Unfinished, for further processingDRUG FOR FURTHER PROCESSING | Since Apr 28, 2026Certified through Dec 31, 2027 | 1 package
|
| Semaglutide SNACSemaglutide | 0420-9520 | Tablet3 mg | Unfinished, for further processingDRUG FOR FURTHER PROCESSING | Since Sep 20, 2019Certified through Dec 31, 2027 | 1 package
|
| Semaglutide SNACSemaglutide | 0420-9530 | Tablet7 mg | Unfinished, for further processingDRUG FOR FURTHER PROCESSING | Since Sep 20, 2019Certified through Dec 31, 2027 | 1 package
|
| Semaglutide SNACSemaglutide | 0420-9540 | Tablet14 mg | Unfinished, for further processingDRUG FOR FURTHER PROCESSING | Since Sep 20, 2019Certified through Dec 31, 2027 | 1 package
|
| Semaglutide | 0420-9008 | Powder1 g/g | Bulk ingredientBULK INGREDIENT | Since Dec 6, 2017Certified through Dec 31, 2027 | 1 package
|
| Semaglutide | 0420-9511 | Powder1 g/g | Bulk ingredientBULK INGREDIENT | Since Nov 10, 2021Certified through Dec 31, 2027 | 1 package
|
| Liraglutide | 0420-9006 | Powder1 g/g | Bulk ingredientBULK INGREDIENT | Since Feb 1, 2011Certified through Dec 31, 2026 | 1 package
|
The rest of its federal record
Checked against every GLP-1 record we publish from FDA. A recall or shortage counts when FDA printed one of this firm’s NDCs in it; a letter or 503B entry counts when the firm name matches exactly. Similar names are listed apart and not counted.
503B outsourcing facility register
Not on the register under this name.
GLP-1 warning letters
GLP-1 recalls
- Class II, ongoing, reported Jan 7, 2026: Presence of Particulate Matter: Hair was found in a prefilled syringeD-0244-2026 · Novo Nordisk Inc. · matched by name
- Class II, ongoing, reported Jan 7, 2026: Presence of Particulate Matter: Hair was found in a prefilled syringeD-0245-2026 · Novo Nordisk Inc. · matched by name
- Class II, terminated, reported Apr 21, 2021: Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.D-0617-2021 · Novo Nordisk Inc · matched by name
- Class II, terminated, reported Apr 21, 2021: Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.D-0618-2021 · Novo Nordisk Inc · matched by name
- Class II, terminated, reported Apr 21, 2021: Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.D-0622-2021 · Novo Nordisk Inc · matched by name
- Class I, terminated, reported Apr 21, 2021: Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.D-0623-2021 · Novo Nordisk Inc · matched by name
FDA enforcement reports, updated by FDA Sep 23, 2026. Every GLP-1 recall
FDA drug shortage list
None of this firm’s NDCs is on FDA’s GLP-1 shortage entries.
FDA drug shortages ↗, updated by FDA Oct 2, 2026.
What these listings mean, and what they do not
- Unfinished, for further processing. Drug made to be processed further by another firm (filled, packed or finished elsewhere), not sold to patients in this form.
- Bulk ingredient. The active ingredient itself, as powder or solution, sold to manufacturers or, where the listing says so, to compounders. A listing tells FDA the firm makes or sells it; it is not an approval of the ingredient or of anything made from it.
A listing is not an approval, and not a quality check. It tells FDA a firm makes, labels or compounds a drug. Whether a product was approved is a question about its application, shown above where there is one. Whether a plant passed inspection is a different record again.
The molecules. Semaglutide is the ingredient in Ozempic, Wegovy, Rybelsus; Liraglutide is the ingredient in Victoza, Saxenda.
“Inclusion in the NDC Directory does not indicate that FDA has verified the information provided or that the products are FDA-approved.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗
“Assignment of an NDC number does not in any way denote FDA approval of the product.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗
“The content of each NDC Directory entry is the responsibility of the labeler submitting the SPL file.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗
Related records
Other firms listing semaglutide and liraglutide
FDA registers on this site
Sources
- FDA NDC directory via openFDA ↗, updated by FDA .
- FDA’s National Drug Code Directory page ↗ for the quoted definitions.
- Read by us Oct 4, 2026. Not medical advice; this page describes filings, not products’ safety.